CN107582822A - A kind of composition and its preparation and preparation method for being used to treat rhinitis - Google Patents
A kind of composition and its preparation and preparation method for being used to treat rhinitis Download PDFInfo
- Publication number
- CN107582822A CN107582822A CN201710868863.4A CN201710868863A CN107582822A CN 107582822 A CN107582822 A CN 107582822A CN 201710868863 A CN201710868863 A CN 201710868863A CN 107582822 A CN107582822 A CN 107582822A
- Authority
- CN
- China
- Prior art keywords
- composition
- paste
- rhinitis
- parts
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a kind of composition and its preparation and preparation method for being used to treat rhinitis, said composition is mainly prepared by bulk drugs such as Flos Magnoliae Liliflorae, maggot, tooth soap, palm grass according to different parts by weight, said composition can treat all kinds rhinitis such as seasonal rhinitis, rhinitis chronic, atrophic rhinitis, concha hypertrophy, and the sneezing as caused by rhinitis, rhinorrhea, nasal obstruction, headache, decrease of memory, hyposphresia, eye be dry and the symptoms such as eye is itched, and pharyngitis can be treated.
Description
Technical field
The present invention relates to the field of Chinese medicines, more particularly to a kind of composition for being used to treat rhinitis and its preparation and preparation side
Method.
Background technology
Rhinitis, i.e. nasal cavity inflammatory disease, it is virus, bacterium, allergen, various physical and chemical factors and some systemic diseases
The inflammation of caused bronchia mucosal, the main pathological change of rhinitis is bronchia mucosal hyperemia, swelling, ooze out, hyperplasia, atrophy or bad
Wait indefinitely, and for the generation of coryza, familial inheritance only account for 10% or so factor, and remaining 80% is all to make the day after tomorrow
Into.Mention rhinitis, current treatment method mainly has three kinds, and first, take common drug orally, but take medicine for a long time to liver and kidney
Can have an impact, can only be used as short-term symptom management, it is impossible to from the pathocure rhinitis of rhinitis；Second, hormone medication, a lot
Patient by spray vasoconstriction medicament, play hormone pin, antibioticses medicament treats rhinitis, but because be related to hormone drugs,
Can only short-period used, it is long-term easily to produce dependence and drug resistance and aggravate the state of an illness；3rd, open surgery, for rhinitis, greatly
Partial Hospitals can all suggest operative treatment, and bronchia mucosal is very fragile, operate on dangerous of performing an operation, the wound of formation is permanent
Property, once recurrence can be more serious, the later stage is difficult to cure and double pain, therefore, selects a kind for the treatment of side of safe and secure
Formula is particularly important.
The content of the invention
Rhinitis controls the problems such as refractory long in order to solve in the prior art, and the invention provides a kind of group for being used to treat rhinitis
Compound and its preparation and preparation method, said composition good effect is quick without any hormone and antibiotic, efficient and control
More rate is high, and without toxic side effect, children, pregnancy period and the women breast-feeding their children of more than 3 years old can use.
Concrete technical scheme of the present invention is as follows:
The invention provides the composition for treating rhinitis, said composition is mainly prepared by the bulk drug of following parts by weight
Form:
The present invention show that the composition formed using above bulk drug can treat seasonal nose by largely testing
The all kinds rhinitis such as inflammation, rhinitis chronic, atrophic rhinitis, concha hypertrophy, and sneeze, have a running nose as caused by rhinitis,
Nasal obstruction, headache, decrease of memory, hyposphresia, eye be dry and the symptoms such as eye is itched.
Further improve, preparing the raw materials used medicine of said composition also includes the composition of following parts by weight:
Palm grass 20-40 exists everywhere 10-25.
Further improve, composition is mainly prepared by the bulk drug of following parts by weight:
After the present invention adds palm grass and existed everywhere in the composition, the effect for the treatment of rhinitis is further increased,
Meanwhile it is set to possess the effect for the treatment of pharyngitis.
Another aspect of the present invention additionally provides the preparation method of said composition, and this method comprises the following steps:
1) after each material is weighed in proportion, it is positioned in baking oven and dries, obtains dry product；
2) dry product that step 1) obtains is ground into powder, sieved, residual powder continues to grind, until whole mistakes
Sieve, obtains drug powder；
3) using solid-liquid ratio as 1g:10-15ml ratio is separately added into the drug powder and the aqueous solution of step 2) acquisition, with strong
Electric field extracts 60min, and electric-field intensity is 80-100 kilovolts every square centimeter, and it is 500-800 times that high voltage electric field, which rushes number, pulse frequency
For 300-350Hz, pharmaceutical extraction liquid is obtained, is centrifuged, takes supernatant, precipitation repeats above step 3 times, merges each secondary supernatant
Liquid；
4) supernatant concentration for obtaining step 3), drying, is produced.
The composition prepared by above method can significantly improve the content of active ingredient in medicine, make the combination of preparation
Thing has more preferable therapeutic effect to rhinitis and pharyngitis.
In order to reach the effect of sustained release, said composition is prepared paste making agent by the present invention, wherein, the weight of composition and auxiliary material
Portion rate is 1:0.5-5.
Further improve, auxiliary material includes parts by weight and gathered for 5-10 parts polyglyceryl fatty acid ester, 1-5 parts shellac, 0.2-1 parts
Lactic acid and 15-20 part vaseline, the mixing that the present invention passes through addition polyglyceryl fatty acid ester, shellac and PLA in paste
Thing, it is formed microballoon with composition, then paste making agent is modulated with vaseline, make paste that there is slow releasing function.
Further improve, paste is 0.1-1 parts peppermint oil, 0.2-0.5 parts cinnamon essential oil and 1-1.8 also including parts by weight
Part tarragon essential oil.
It is fast to can reach action by the mixture of addition peppermint oil, cinnamon essential oil and tarragon essential oil in paste by the present invention
The effect of fast, and then play a role to greatest extent.
Further improve, the pH to 6.3-6.8 of paste is adjusted with triethanolamine and watery hydrochloric acid.
The present invention makes it have optimal stickiness, convenient coating by the way that the pH value of paste is transferred into 6.3-6.8.
Composition provided by the invention can be prepared into medicine, and said composition has the effect of notable to rhinitis, can be used for simultaneously
Treat pharyngitis.
Embodiment
Embodiment 1
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 2
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 3
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 4
A kind of composition, said composition are made up of the composition of following parts by weight:
The preparation method of said composition is:
1) after each material is weighed in proportion, it is positioned in baking oven and dries, obtains dry product；
2) dry product that step 1) obtains is ground into powder, sieved, residual powder continues to grind, until whole mistakes
Sieve, obtains drug powder；
3) using solid-liquid ratio as 1g:10ml ratio is separately added into the drug powder and the aqueous solution of step 2) acquisition, uses forceful electric power
Field extraction 60min, electric-field intensity are 80 kilovolts every square centimeter, and high voltage electric field rushes number as 500 times, pulse frequency 300Hz, obtains
To pharmaceutical extraction liquid, centrifuge, take supernatant, precipitation repeats above step 3 times, merges each secondary supernatant and merges each secondary supernatant
Liquid；
The supernatant concentration that step 3) is obtained, drying, is produced.
Embodiment 5
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 6
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 7
A kind of composition, said composition are made up of the composition of following parts by weight:
Embodiment 8
A kind of composition, said composition are made up of the composition of following parts by weight:
The preparation method of said composition is:
1) after each material is weighed in proportion, it is positioned in baking oven and dries, obtains dry product；
2) dry product that step 1) obtains is ground into powder, sieved, residual powder continues to grind, until whole mistakes
Sieve, obtains drug powder；
3) using solid-liquid ratio as 1g:15ml ratio is separately added into the drug powder and the aqueous solution of step 2) acquisition, uses forceful electric power
Field extraction 60min, electric-field intensity are 100 kilovolts every square centimeter, and high voltage electric field rushes number as 800 times, pulse frequency 350Hz,
Pharmaceutical extraction liquid is obtained, is centrifuged, takes supernatant, precipitation repeats above step 3 times, merges each secondary supernatant and merges on each time
Clear liquid；
4) supernatant concentration for obtaining step 3), drying, is produced.
The paste of embodiment 9
The parts by weight of each composition of paste are:
The paste of embodiment 10
The parts by weight of each composition of paste are:
The paste of embodiment 11
The parts by weight of each composition of paste are:
The paste of embodiment 12
The parts by weight of each composition of paste are:
The preparation method of paste:
1) composition is prepared according to the method for embodiment 5；
2) it is in 15 parts of ethanol, as solvent phase, by polyglyceryl fatty acid ester shellac and PLA to be dissolved in into parts by weight
30 parts of aqueous solution are dispersed in the composition obtained by step 1), as aqueous phase, solvent is added in aqueous phase, uses magnetic force
Agitator stirs under the conditions of 800r/min, -5 DEG C, spray drying, with petroleum ether three times, is positioned in baking oven, 80
DEG C drying, obtains dry compositions powder.
3) the dry compositions powder obtained by step 2) is added in vaseline and stirred, produced.
The paste of embodiment 13
The parts by weight of each composition of paste are:
The paste of embodiment 14
The parts by weight of each composition of paste are:
The paste of embodiment 15
The parts by weight of each composition of paste are:
The paste of embodiment 16
The parts by weight of each composition of paste are:
The preparation method of paste:
1) composition is prepared according to the method for embodiment 5；
2) shellac and PLA are dissolved in parts by weight as in 8 parts of ethanol, as solvent phase, by polyglyceryl fatty acid ester and
Composition obtained by step 1) is dispersed in 20 parts of aqueous solution, and as aqueous phase, solvent is added in aqueous phase, stirred with magnetic force
Mix device to stir under the conditions of 800r/min, -5 DEG C, be spray-dried, with petroleum ether three times, be positioned in baking oven, 80 DEG C
Dry, obtain dry compositions powder；
3) the dry compositions powder obtained by step 2) is added in 10-15 part vaseline and stirred, obtain paste；
4) peppermint oil, cinnamon essential oil, tarragon essential oil are stirred with magnetic stirring apparatus with 200r/min speed, obtained mixed
Close essential oil；
5) mixed essential oil obtained by step 4) is slowly added to stir in the paste that step 3) obtains with 400r/min speed
Mix uniformly, produce.
Embodiment 17
It is in place of a kind of paste, with the difference of embodiment 11, the pH value that paste is adjusted with triethanolamine and watery hydrochloric acid is
6.3。
Embodiment 18
It is in place of a kind of paste, with the difference of embodiment 11, the pH value that paste is adjusted with triethanolamine and watery hydrochloric acid is
6.5。
Embodiment 19
It is in place of a kind of paste, with the difference of embodiment 11, the pH value that paste is adjusted with triethanolamine and watery hydrochloric acid is
6.8。
Reference examples 1
A kind of to be used to treat the composition of rhinitis, the difference with embodiment 2 is, add parts by weight be 5 it is windproof.
Reference examples 2
A kind of composition for being used to treat rhinitis, the difference with embodiment 2 is, deletes radix glycyrrhizae.
Reference examples 3
A kind of composition for being used to treat rhinitis, the difference with embodiment 2 is, radix glycyrrhizae is substituted for into honeysuckle.
Reference examples 4
A kind of composition for being used to treat rhinitis, the difference with embodiment 6 are, add the mountain that parts by weight are 10
Short, bristly hair or beard.
Reference examples 5
A kind of composition for being used to treat rhinitis, the difference with embodiment 6 is, deletes and exists everywhere.
Reference examples 6
A kind of composition for being used to treat rhinitis, the difference with embodiment 6 is, palm grass is substituted for Rhododendron dauricum.
The paste of reference examples 7
The parts by weight of each composition of paste are:
The paste of reference examples 8
The parts by weight of each composition of paste are:
Shellac 3.26
PLA 8.26
Vaseline 18.48.
The paste of reference examples 9
The parts by weight of each composition of paste are:
The paste of reference examples 10
The parts by weight of each composition of paste are:
The paste of reference examples 11
The parts by weight of each composition of paste are:
The paste of reference examples 12
Reference examples 13
It is in place of a kind of paste, with the difference of embodiment 18, the pH value that paste is adjusted with triethanolamine and watery hydrochloric acid is
5.5。
Reference examples 14
It is in place of a kind of paste, with the difference of embodiment 18, the pH value that paste is adjusted with triethanolamine and watery hydrochloric acid is
7.5。
The effect of test example 1 compares
The effect of a pair of rhinitis
1 rhinitis animal model:
Model group:20 μ g egg proteins and 2mg aluminium hydroxides are added into 0.5mLNaCl (0.9%) to be suspended, in modeling the 1st, 2,
5th, 8 days in being injected intraperitoneally suspension 0.5mL in Mice Body, after modeling the 15-24 days with the continuous drops of 20 μ lNaCl (0.9%)
Nose.
Control group:Normal raising mouse, in modeling the 15-24 days with 20 μ lNaCl (0.9%) continuous collunariums.
Experimental group:20 μ g egg proteins and 2mg aluminium hydroxides are added into 0.5mLNaCl (0.9%) to be suspended, in modeling the 1st, 2,
5th, 8 days in being injected intraperitoneally suspension 0.5mL in Mice Body, with embodiment 1-3,6-7 and the composition of reference examples 1-3,6-7, with
Vaseline modulates paste making agent, is continuously applied within the nasal cavity of mouse within the 15-24 days after modeling, applying amount does not influence mouse and exhaled
Inhale, smear once daily, 10 days courses for the treatment of.
2 mice behavior standards of grading:
Sneeze counts:0 is 0 point, and 1-3 are 1 point, and 4-8 are 2 points, and more than 8 are 3 points；
Nasal mucus length:Do not have a running nose for 0 point, nasal mucus flow to nostril as 1 point, and outflow nostril is 2 points, and delay is had one's face covered with as 3 points；
Disturb nose number:0 time is 0 point, and 1-3 times is 1 point, and more than 3 times are 2 points；
Every group of 5 mouse, take the average value of scoring；Counted in 30 minutes, quantify superposition scoring.
3 results
Above experimental group is administered into after modeling the 24th day, and result of the test is as shown in table 1.
The influence that the composition of table 1 scores mice behavior
As shown in Table 1, the mice behavior scoring of the composition group of embodiment 1-3,6-7 is substantially less than reference examples 1-3,6-
7 composition group, the mice behavior scoring of the composition of embodiment 2 are less than embodiment 1 and 3 groups, the composition group of embodiment 6
Mice behavior scoring less than embodiment 5 and 7 composition group, show that composition provided by the invention has preferably to rhinitis
Therapeutic effect, after the bulk drug in composition provided by the invention reduces or is replaced by other bulk drug, said composition
The therapeutic effect of rhinitis is significantly reduced.
The effect of two pairs of pharyngitis
1 test method
1) mouse hypertrophy cell cancer (P815) cell with DMEM+10%FBS in 37 DEG C, 5%CO2Carry out cellar culture
(10cm culture dishes), when cell growth to logarithmic phase, cell is collected, discard nutrient solution, PBS 3 times, add 3ml
After 0.25% trypsase -0.04%EDTA, 37 DEG C of digestion 2min, 5ml complete medium neutralization reactions are added thereto, are blown
It is transferred to after beating cell in centrifuge tube, 1000rpm centrifugation 5min, adjusts concentration of cell suspension 3 × 104Individual/ml；
2) cell kind is entered in 96 well culture plates, the μ l of cell suspension 180 is added per hole, culture plate is put into cell culture incubator
(37 DEG C, 5%CO2) cellar culture；
3) it is general to grow the embodiments of the invention for 50%-70%, adding identical drug concentration according to cell growth status
5-7, reference examples 4-6 and Patent No. CN102406827A pharyngitis chewable tablets (pharyngitis chewable tablets group), continue to cultivate 24h；
4) 20 μ lMTT solution (5mg/ml, i.e. 0.5%MTT) are added after 24h, continue to cultivate 4h；
5) buckle method removes supernatant after 4h, is gently patted dry with blotting paper, and 200 μ l dimethyl sulfoxide (DMSO)s are added per hole, put shaking table
Upper low-speed oscillation 10min, makes crystal fully dissolve.The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument 490nm；
6) while control wells (cell, the medicine dissolving medium of same concentrations, nutrient solution, MTT, dimethyl sulfoxide (DMSO)) are set,
6 multiple holes of every group of setting.
Result of the test is represented the inhibiting rate of cell with medicine:
Cell proliferation inhibition rate (%)=(control wells OD values-dosing holes OD values)/control wells OD value × 100%.
2 statistical dispositions
Using Microsoft Excel 12003, correlation analysis and student t in software are examined, and data are with mean
± S.D. is represented.
3 experimental results
Experiment is repeated 3 times.Statistical result is shown in Table 2 after mtt assay experiment.
2 composition provided by the invention of table influences result to P815 cell inhibitory effects
As shown in Table 2, embodiment 5-7 composition to P815 cell inhibitory effects apparently higher than reference examples 4-6 and pharyngitis
Chewable tablets group, and the composition of embodiment 6 is better than the group of embodiment 5 and embodiment 7 to P815 cell inhibitory effect positive effects
Compound group, it was demonstrated that provided by the invention that there is good therapeutic effect to pharyngitis containing existing everywhere the composition that is grown grass with palm；
After bulk drug reduces or is replaced by other bulk drug, said composition significantly reduces to the therapeutic effect of pharyngitis.
The cumulative in vitro release rate of test example 2 is tested
The drug release rate detection of paste:With reference to version in 2015《Chinese Pharmacopoeia》The drug release rate inspection of general rule 0931.
Above example 9-11, reference examples 7-9 paste are taken respectively, and using turning blue laws, rotating speed 75r/min, temperature is
37 DEG C, 3h is 750mL2%CTAB and 0.1mol/mL HCL before dissolution medium, rear to add 250mL2%CTAB and 0.2mol/mL
Phosphate buffer, pH 6.8, cumulative volume 1000mL, take cream agent, which is placed in, to be turned in basket, respectively at 1h, 2h, 4h, 6h, 12h,
24h and 48h are separately sampled, and buffer solution drug content is detected with high performance liquid chromatography, and calculate the preparation of medicine,
As a result it is as shown in table 3.
Preparation (%) result of the test of the inventive samples of table 3
Note:"-" represents that medicine no longer discharges substantially in the time.
Embodiment 9-11 paste slowly discharges in 24h as can be seen from Table 3, and reference examples 7-9 paste is in 4h
Inside all release, the slow release effect of embodiment 10 are significantly better than embodiment 9 and embodiment 11, it was demonstrated that 4 parts are added in paste
The mixture of polyglyceryl fatty acid ester, 0.8 part of shellac and 0.2 part of PLA can play more preferable slow release effect, when wherein one
Kind composition is removed or replaced the sustained release performance that can all reduce paste.
The transmitance of test example 3 is tested
Above example 13-15 and reference examples 10-12 paste are taken respectively, are investigated with Franze diffusion cells method and are promoted effect thoroughly
Fruit, result of the test are as shown in table 4.
Table 4 promotees result of the test
As can be seen from Table 4, embodiment 13-15 paste onset time is short, and 15min has generated obvious rush effect thoroughly
Fruit, Percutaneous permeability are higher, hence it is evident that higher than reference examples 10-12 paste, and the Percutaneous permeability of the paste of embodiment 14 is notable
Higher than the paste of embodiment 13 and embodiment 15, it was demonstrated that add 0.15 portion of peppermint oil, 0.1 part of cinnamon essential oil and 0.55 in paste
During the mixture of part tarragon essential oil, the saturating effect of rush of paste is best.
The viscosity of test example 4 is tested
Above example 17-19 and reference examples 13-14 paste are taken respectively, and its viscosity is surveyed with Rotary Viscosimeter
Amount, rotating speed 12r/min, measurement result are as shown in table 5.
The paste viscosity result of the test of 5 different pH value of table
As shown in Table 5, when paste pH is 6.3-6.8, viscosity 38000-53000mPas, moderate viscosity, both facilitated
Coating, will not flow out from patient's nasal cavity again, and when paste pH is 5.5, viscosity 18000mPas is excessively dilute, after coating easily
Flowed out from the nasal cavity of patient, when paste pH is 7.5, viscosity 93000mPas, viscosity is excessive, not easy to apply, it was demonstrated that cream
When the pH of agent is 6.3-6.8, modest viscosity, when pH is raised and lowered, viscosity is undesirable, and when pH is 6.5, viscosity is most
It is good.
Claims (9)
1. a kind of composition for being used to treat rhinitis, it is characterised in that the composition is mainly by the bulk drug of following parts by weight
It is prepared:
2. the composition as claimed in claim 1 for being used to treat rhinitis, it is characterised in that the composition also includes following weight
Measure the composition of part:
Palm grass 20-40 exists everywhere 10-25.
3. the composition as claimed in claim 2 for being used to treat rhinitis, it is characterised in that the composition is mainly by following heavy
The bulk drug of amount part is prepared:
4. a kind of prepare the method for being used to treat the composition of rhinitis described in claim any one of 1-3, it is characterised in that described
Method comprises the following steps:
1) after each material is weighed in proportion, it is positioned in baking oven and dries, obtains dry product；
2) dry product that step 1) obtains is ground into powder, sieved, residual powder continues to grind, until all sievings, are obtained
Drug powder；
3) using solid-liquid ratio as 1g:10-15ml ratio is separately added into the drug powder and the aqueous solution of step 2) acquisition, uses highfield
60min is extracted, electric-field intensity is 80-100 kilovolts every square centimeter, and it is 500-800 times that high voltage electric field, which rushes number, and pulse frequency is
300-350Hz, pharmaceutical extraction liquid is obtained, centrifuged, take supernatant, precipitation repeats above step 3 times, merges each secondary supernatant
Liquid；
4) supernatant concentration for obtaining step 3), drying, is produced.
5. a kind of paste, including the composition and auxiliary material that are used to treat rhinitis described in claim any one of 1-3, its feature exist
In the ratio of weight and number of the composition and auxiliary material is 1:0.5-5.
6. the paste described in claim 5, it is characterised in that the auxiliary material is 5-10 part polyglycerol fatty acids including parts by weight
Ester, 1-5 parts shellac, 0.2-1 parts PLA and 15-20 part vaseline.
7. the paste described in claim 6, it is characterised in that the paste also include parts by weight be 0.1-1 parts peppermint oil,
0.2-0.5 parts cinnamon essential oil and 1-1.8 part tarragon essential oils.
8. paste as claimed in claim 5, it is characterised in that the pH to 6.3- of paste is adjusted with triethanolamine and watery hydrochloric acid
6.8。
9. the composition described in claim any one of 1-3 is preparing the application in being used to treat the medicine of rhinitis and pharyngitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710868863.4A CN107582822A (en) | 2017-09-22 | 2017-09-22 | A kind of composition and its preparation and preparation method for being used to treat rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710868863.4A CN107582822A (en) | 2017-09-22 | 2017-09-22 | A kind of composition and its preparation and preparation method for being used to treat rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107582822A true CN107582822A (en) | 2018-01-16 |
Family
ID=61047742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710868863.4A Pending CN107582822A (en) | 2017-09-22 | 2017-09-22 | A kind of composition and its preparation and preparation method for being used to treat rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107582822A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125580A (en) * | 2018-10-10 | 2019-01-04 | 万滢 | A kind of medicament for treating rhinitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931247A (en) * | 2006-09-28 | 2007-03-21 | 成都南山药业有限公司 | Medicine for treating rhinitis and its prepn process |
-
2017
- 2017-09-22 CN CN201710868863.4A patent/CN107582822A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931247A (en) * | 2006-09-28 | 2007-03-21 | 成都南山药业有限公司 | Medicine for treating rhinitis and its prepn process |
Non-Patent Citations (1)
| Title |
|---|
| WEI PENG等: "Anti-allergic rhinitis effect of caffeoylxanthiazonoside isolated fromfruits of Xanthium strumarium L. in rodent animals", 《PHYTOMEDICINE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125580A (en) * | 2018-10-10 | 2019-01-04 | 万滢 | A kind of medicament for treating rhinitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2653085C (en) | Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof | |
| CN102264372B (en) | Fulvestrant nanosphere/microsphere and preparative method and use thereof | |
| CN104042571B (en) | It is loaded with preparation method and the gel micro-ball of preparation thereof of the pH sensitive type gel microsphere of capsaicin | |
| Zhou et al. | Mucus-penetrating polymeric nanoparticles for oral delivery of curcumin to inflamed colon tissue | |
| Singh et al. | Formulation and evaluation of herbal gel containing ethanolic extract of ipomoea fistulosa | |
| CN103417559B (en) | Animal compound suspension injection containing ivermectin and praziquantel and preparation method thereof | |
| CN103977422B (en) | Guanidine class antidiabetic drug-polysaccharide conjugate and its production and use | |
| CN107582822A (en) | A kind of composition and its preparation and preparation method for being used to treat rhinitis | |
| CN116942847B (en) | Drug-loaded plant exosome targeting hair follicle, and preparation method and application thereof | |
| CN103989746B (en) | A kind of broussoflavone nanometer formulation and preparation method thereof | |
| CN104224969B (en) | A kind of Flos Mali Hallianae leaf extract, extracting method and purposes | |
| Zhao et al. | Green synthetic natural carbon dots derived from Fuligo Plantae with inhibitory effect against alcoholic gastric ulcer | |
| CN105496942B (en) | A kind of preparation method of highly dissoluble curcumin liquid crystal | |
| Agrawal et al. | In-Vitro anthelmintic activity of Kaempferia rotunda. | |
| WO2023040094A1 (en) | Composition having effect of inhibition of tumor cell activity and application of composition | |
| Prasetyo et al. | Formulation and characterization of nanoemulsion of tread leave ethanol extract (Catharanthus roseus (L.) G. Don) as antihyperglycemic | |
| CN105535933A (en) | Leuprorelin medicinal composition injection type hypodermic implantation agent | |
| Cheng et al. | Higher frequency electrical stimulation enhanced myloglossus satellite cell differentiation by upregulating expression of Pax7 mRNA, MyoD, myogenin and MyHC protein. | |
| CN113876966B (en) | Fluorescent probe for subtype identification of macrophages in vivo, and preparation method and application thereof | |
| CN104288142B (en) | The xylocarpus granatum element H and the like purposes in preparing anti-depression drug or food | |
| Vidhya et al. | Evaluation of Phytochemicals and Anticancer Potential of C. maxima: An In-silico Molecular Docking Approach | |
| CN114470229A (en) | Preparation and application of carrier-free double-drug self-assembly nanoparticles | |
| CN104414997A (en) | Sodium ferrous chlorophyll capsule | |
| CN105687195A (en) | Application and method of quinine dihydrochloride to secreting gland disease treatment and medicine composition | |
| CN103083248B (en) | Polysaccharide sulfate dry suspension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180116 |
|
| RJ01 | Rejection of invention patent application after publication |